Samir Ghodbane, Ph.D., has been appointed as the new general manager of CMC services and CTM manufacturing at Frontage. Dr. Ghodbane has extensive experience and expertise in product development and technical operations spanning the complete product development cycle, as well as a comprehensive understanding of branded and generic pharmaceutical environments. He has led drug development and technical services at Actavis, Alpharma, and Wyeth. Most recently, he served as vice president of product development and technical services at Actavis, where he oversaw an organization of 180 people located at three different locations.

Daniel Tang, Ph.D., has been appointed vice president of DMPK and bioassay at the company’s operations in Shanghai. Dr. Tang brings experience from ChemPartner, where he managed DMPK operations and business development. He also served as director of bioanalytical services at Quest Pharmaceutical Services and supervised a bioanalytical group of thirteen scientists conducting GLP bioanalysis.

Ron Connolly has been appointed to a new role as senior vice president of business development.Mr. Connolly will be responsible for sales, marketing, and strategic business initiatives at Frontage. He has held several roles at Frontage, including developing and expanding client relationships, as well as various operational roles as head of U.S. operations.In addition, Ron has 20 years of drug development and FDA inspection experience from Flavine, Wyeth, Sanofi Aventis, and GlaxoSmithkline.

“The strategic hiring of Daniel and Samir will add to the experience of our senior management team, providing management to some of our key service areas of growth opportunities both in the U.S. and China,” stated president and chief executive officer Song Li, Ph.D. “Additionally, transitioning Ron to business development will help the development of our sales organization through his in-depth industry experience, providing Frontage the ability to continue to grow our core service offerings.”